Q3 FY23 Business Update Webinar Notification
April 11 2023 - 6:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company that has developed
two commercially available oral immunotherapeutic products for the
treatment of gut mediated diseases, is pleased to advise it will
provide a business update for the quarter ended 31 March 2023 (Q3
FY23).
Investors are invited to join a live webcast and
Q&A hosted by Immuron CEO Steven Lydeamore on
Wednesday, 19 April 2023 at 11:00am (AEST).
To register for the webinar, please click on
this link:
https://us02web.zoom.us/webinar/register/WN_TpvaXZZ1QDG1FnZdXdtSGA
After registering, you will receive a
confirmation email containing information about joining the
webinar.
COMPANY CONTACT:Steven
LydeamoreChief Executive OfficerPh:+61 (0)3 9824
5254info@immuron.com
About Travelan®Travelan® is an orally
administered passive immunotherapy that prophylactically reduces
the likelihood of contracting travelers’ diarrhea, a digestive
tract disorder that is commonly caused by pathogenic bacteria and
the toxins they produce. Travelan® is a highly purified tabletized
preparation of hyper immune bovine antibodies and other factors,
which when taken with meals bind to diarrhea-causing bacteria and
prevent colonization and the pathology associated with travelers’
diarrhea. In Australia, Travelan® is a listed medicine on the
Australian Register for Therapeutic Goods (AUST L 106709) and is
indicated to reduce the risk of Travelers’ Diarrhea, reduce the
risk of minor gastro-intestinal disorders and is antimicrobial. In
Canada, Travelan® is a licensed natural health product (NPN
80046016) and is indicated to reduce the risk of Travelers’
Diarrhea. In the U.S., Travelan® is sold as a dietary supplement
for digestive tract protection.
About Travelers’ diarrheaTravelers’ diarrhea is
a gastrointestinal infection with symptoms that include loose,
watery (and occasionally bloody) stools, abdominal cramping,
bloating, and fever, Enteropathogenic bacteria are responsible for
most cases, with enterotoxigenic Escherichia coli (ETEC) playing a
dominant causative role. Campylobacter spp. are also responsible
for a significant proportion of cases. The more serious infections
with Salmonella spp. the bacillary dysentery organisms belonging to
Shigella spp. and Vibrio spp. (the causative agent of cholera) are
often confused with travelers’ diarrhea as they may be contracted
while travelling and initial symptoms are often
indistinguishable.
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024